VER
Vascular & Endovascular Review

Institutional Case Analysis of Low Dose CT in Lung Cancer Screening for High-Risk Patient Populations

Kunal Pingale[1], Adithya S Nair[1*], Siddharth Pande[2]

[1] Department of Radio-diagnosis, Dr D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra 411018, India

[2] Department of Radio-diagnosis, Dr D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra 411018, India

[*] Corresponding author, Adithya S Nair, Department of Radio-diagnosis, Dr D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra 411018, India Email: nairadithya77@gmail.com

ABSTRACT

Lung cancer is the number one cause of cancer-related deaths in the world and late-stage diagnosis is one of the factors that lead to poor survival chances. In case of high-risk patients, especially chronic smokers, low-dose CT (LDCT) has become a game-changer in cancer screening as it provides the opportunity to detect small nodules in the lungs early at an early stage, and this shows a great deal of improvement in the clinical outcome. The current institutional case analysis assesses the effectiveness of the LDCT screening strategy, basing their effectiveness on the outcome of mortality reduction, uptake of screening, the diagnostic image accuracy and the impact of the institutional implementation.

The paper utilizes the secondary data of seminal trials like the NLST and NELSON, institutional reports, and published literature, and this makes it strong in terms of evidence base. Thematic analysis strategy was used to integrate common patterns in various sources, such as screening barriers, patient engagement strategies, and practices in institutions. The combination of validated quantitative results and qualitative understanding of systemic issues offers a breadth and depth of this dual methodology.

Findings prove that LDCT minimizes the deaths of lung cancer by 2024 percent, doubles the stage I diagnoses, and increases the survival rate when made a part of the institutional practice. Nevertheless, adoption is still very low, with less than 20 per cent of those who are eligible being screened, which is indicative of inherent system barriers, including inequity in access and perceptions of patients. The success of a program is heavily dependent on the institutional implementation, where standardised imaging protocols with patient navigation services enhance the quality of diagnostic testing and attendance.

This discussion has determined that LDCT is an important breakthrough in lung cancer screening; however, it can only achieve its full potentials when it goes beyond institutional and systemic obstacles to exploit the opportunities presented by high risk groups.

Keywords - Institutional Analysis, Low Dose CT, Lung Cancer, Cancer Screening, High Risk, Diagnostic Imaging, Early Detection

How to Cite: Kunal Pingale, Adithya S Nair, Siddharth Pande, (2024) Institutional Case Analysis of Low Dose CT in Lung Cancer Screening for High-Risk Patient Populations., Vascular and Endovascular Review, Vol.7, No.4, 50-56

INTRODUCTION

Lung cancer has been known to be the major cause of death resulting from cancer in the world; this is because by the time it is diagnosed, it is mostly in its advanced stages, and thus, treatment is not possible. In high-risk groups, namely, long-term smokers and those who have high exposure to tobacco, early detection plans are essential. Low Dose Computed Tomography (LDCT) has become the gold standard in screening for lung cancer with high sensitivity (97) and specificity (95) and less radiation exposure compared to traditional CT scans. Large cohort studies, including the SUMMIT trial, show that LDCT screening has the ability to detect small nodules in the lungs earlier in their development, which greatly improves the outcome of survival and decreases the mortality rate of lung cancer. Notably, early diagnosis increases the five-year survival chances from about 10 percent in late cancer diagnosis to about 65 percent when the cancer is detected at an early stage. Although the application of LDCT screening is proven to be effective, its uptake is still low, with less than half (18 percent) of eligible individuals screening having done so in the U.S., which reflects institutional and systemic barriers to interventions. The analysis of the institutional cases is thus needed to assess the protocols of diagnostic imaging, the engagement of the patients, and the clinical outcomes, and make sure that LDCT screening programs successfully enter the healthcare systems. Such analyses can contribute to the process of improving early detection, lowering mortality and improving long-term clinical outcomes by including the issues related to cancer screening in high-risk groups of patients.

LITERATURE REVIEW

Bonney et al. (2022) state that low Dose Computed Tomography (LDCT) has become one of the standards in screening for lung cancer in the high-risk group of patients, especially long-term smokers and those with heavy tobacco exposure. Zhong et al., (2024) highlights that the randomised controlled trials (RCTs), like the National Lung Screening Trial (NLST) and the NELSON trial showed that LDCT decreases lung cancer mortality by about 2024 percent relative to chest radiography, which proved that it can be used in early-detection strategies. In the NLST, more than 53,000 participants were enrolled at the age of 55-74 years with a smoking history of 30 pack-years or more; the results of the study indicated a big difference in clinical outcomes, as the presence of the cancers was identified in earlier stages. Equally, the NELSON trial affirmed.

that LDCT screening resulted in earlier detection of smaller nodules, which translated to increased survival.

In spite of good evidence, institutional analysis shows that there are still challenges in implementation. Siddique *et al. (2024)* state that the Uptake is low, as less than one out of every five eligible persons are screened in the U.S., and is indicative of barriers: lack of awareness, access imbalances, and fears of false positives. Although false positives are frequent, they are overcome with the help of organized diagnostic imaging guidelines, such as Lung-RADS, which standardize reporting and minimize unnecessary interventions. Besides, cost-effectiveness literature points to the fact that LDCT screening is most useful when it is focused on high-risk groups to balance resource allocation with the possible mortality reduction.

Bonney *et al*., (2022) state that recent reviews underscore the significance of case study assessment at the institutional level in order to determine the extent of program integration, patient engagement and long-term clinical outcomes. These reviews give information on how to streamline screening pathways, provide equal access, and improve follow-up procedures. Taken together, the literature highlights the fact that LDCT not only can be used as a potent tool in terms of cancer screening but also is an essential part of prevention and health promotion strategies in the world related to the decreased number of people with lung cancer.

METHOD

The methodological benefits of secondary data and thematic analysis can be of great help in this study (Remawi,Gadoud & Preston, 2023). The secondary data, which is based on the large scale trials, institutional reports and published literature has a strong evidence base to assess low dose CT in lung cancer screening among the high risk patient groups. It has the benefit of enabling researchers to gain access to detailed datasets that would be both expensive and impractical to create de novo, so that the results are based on proven clinical outcomes, as well as proven diagnostic imaging protocols. Thematic analysis supplements this as it allows identifying recurring patterns using a variety of sources, including barriers to screening uptake, institutional implementation issues, and methods to increase the rate of early detection (Kaur *et al.*, 2024). Through coding and categorization of themes, researchers will be able to critically synthesise knowledge on the effects of institutional practices on the effectiveness of cancer screening. The combination of these two strategies will guarantee that the methodology is rigorous: on the one hand, secondary data will guarantee breadth and reliability, and on the other hand, thematic analysis will guarantee depth and background knowledge (Fel *et al*., 2023). Combined, they provide a rational, evidence-based approach to the institutional case analysis, emphasizing the demonstrated advantages of LDCT and the systemic obstacles, which have to be overcome to ensure the highest possible results in the high risk cohort.

RESULTS

Mortality Reduction Outcomes

The analyses of institutional cases are always emphatic on the role of low dose CT to decrease the mortality rates due to lung cancer in high risk groups of patients. The National Lung Screening Trial (NLST) indicated a twenty percent decrease in specific mortality due to lung cancer relative to the chest radiography, making LDCT the most proven screening modality of cancer at an early stage (Chalian *et al.,* 2022).



Figure 1: Overestimation of screening-related complications in the National Lung Screening Trial

(Source: Kamel, Kariyawasam & Stiles, 2022)

Equally, the NELSON trial in Europe revealed a 24 percent reduction in mortality especially in male study participants and should also increase benefits by women. These results emphasize the significance of early-stage diagnosis in changing the survival curve because patients diagnosed with stage I or II demonstrate much more favorable clinical outcomes in comparison with patients diagnosed with the disease in its later stages. The institutional data also indicate that the maximum of mortality benefits have been achieved when the screening programs are thoroughly incorporated in the healthcare system so that the follow-ups and compliance with the diagnostic imaging procedures are consistent. The LDCT screening is cost-effective, and by focusing on high-risk populations, it not only prevents deaths but also improves the cost-effectiveness since resources are targeted on those individuals who are most likely to benefit (Behr *et al*., 2023). Taken together, these findings indicate that LDCT screening is a groundbreaking intervention in terms of lowering death rates in lung cancer, and institutional adoption is a key determinant of the long-term maintenance of survival benefits.

Early Detection Rates

Low-dose CT has the strongest case to support its usefulness, as it has been shown that in high-risk groups of patients, it has high early detection rates of lung cancer (Shi *et al*., 2022). LDCT detects tiny nodules in the lungs that are usually less than 10 mm in size and not seen in the chest X-rays, and thus, early detection of the nodules is possible before the onset of symptoms. According to the NLST, 57% of cancers detected by means of LDCT were stage I as compared to 13% of the cancers detected in the control group.



Figure 2: Automated CT analysis predicts vertebral levels, extends FOV, segments muscle and fat, and calculates body composition indices accurately.

(Source: Europe.com. 2023)

Equally, the NELSON trial revealed that LDCT screening increased the rate of detection in stage I or II cancer by a factor of two, and this was very beneficial in clinical outcomes (Pires *et al.*, 2024). Institutional case studies were able to confirm that structured diagnostic imaging protocols, like Lung-RADS, improve the detection rates and also minimize false positives. Notably, stage I cancers have a higher survival rate of over 65 years compared to the lower 10 years (stage IV), which translates to higher survival chances at an earlier stage. These results demonstrate the importance of LDCT in cancer screening, especially in high-risk groups where the morbidity of late-stage cancer is most heavily burdened. It has been highlighted in institutional analyses that to maintain high rates of early detection, patient adherence, and standardised reporting is important to ensure that maximum life is saved through LDCT (Bonney *et al.*, 2022).

Screening Uptake in High-Risk Groups

Although there is strong evidence supporting the use of low-dose CT as a screening tool in lung cancer, institutional analysis has shown that despite their efficacy, there has been a consistent problem in ensuring high screening rates in the high-risk groups of patients. The United States is one of the nations where less than 20 percent of eligible people are screened by LDCT, and this is due to the barriers of inadequate awareness, socioeconomic differences, and the problems of geographic accessibility (Cavers *et al.*, 2022).



Figure 3: Low-dose computerized tomography (LDCT) screening barriers include barriers for providers, barriers for patients, screening and treatment concerns

(Source: Zarinshenas *et al.*, 2023)

Institutional case studies have revealed that uptake is enhanced when healthcare systems proactively approach patients by using specialized outreach, patient education, and simplified referral channels. To illustrate, the programs incorporating LDCT into regular clinical care reports show increased patient participation, especially when the primary care providers are personally engaged in patient counselling. Nonetheless, the uptake is uneven with regard to demographics, with the minority groups and rural population using fewer. This gap explains the necessity of institutional theories that focus on equity in cancer screening. There is also some evidence that false positives and radiation risk perceptions discourage patients from participating, even though the use of LDCT has been proven safe and effective. Institutional analyses indicate that clear communication, patient navigation services, and insurance coverage policies are vitally important to enhance the uptake of screening (Bonney *et al.*, 2022). Finally, it is important to ensure as many high-risk groups as possible are maximally involved so as to achieve the full benefits of mortality reduction and clinical outcomes that have been shown in large trials.

Diagnostic Imaging Accuracy

Institutional case analyses are based on the accuracy and reliability of diagnostic imaging in low-dose CT screening. The sensitivity and specificity of LDCT is better than those of chest radiography, and the sensitivity rates of the LDCT are higher than those of chest radiography to detect small nodules (more than 90%). The false positives are however an issue with the NLST reporting close to 25 per cent of the first scans with findings suggesting suspiciousness, with most being benign. Standardized reporting, fewer interventions that are unnecessary interventions, and better accuracy in diagnosis have been developed as institutional protocols, including Lung-RADS (Mao *et al.*, 2024). The systems are organised in such a way that the nodules are grouped according to size, morphology, and growth rate to provide an effective follow-up and reduce the anxieties of the patients. The case studies prove that increasing the use of Lung-RADS in institutions results in reduced false-positive rates, as well as more effective resource use (Hammer & Hunsaker, 2022).



Figure 4: Normal chest radiography in upright position

(Source: Tárnoki, Karlinger & Ridge, 2024)

In addition to that, the improvements in computer-aided detection and artificial intelligence are only improving the diagnostic accuracy of LDCT, assisting radiologists in identifying the malignant and benign results. The institutional studies also highlight that diagnostic accuracy is not merely a technical problem but a systemic problem because it needs adequate training, quality control, and interdisciplinary teamwork (Pires *et al.*, 2024). LDCT screening programs provide high diagnostic accuracy, which means that they provide reliable early detection, improve clinical outcomes, and increase confidence of cancer screening in high risk patient groups.

Institutional Implementation Impact

Low-dose CT screening programs that are implemented throughout the institution influence the outcomes of lung cancer in high-risk groups of patients significantly. The case analysis demonstrates that more cohesive LDCT programs in the institution lead to a higher rate of screening uptake, higher rates of early detection and positive clinical outcomes in comparison to disjointed programs (Tárnoki, Karlinger & Ridge, 2024). Effective implementation entails coordination of diagnostic imaging procedures, patient navigation services and multidisciplinary pathways.



Figure 5: Suspicious Atypical Cystic Airspace Lesions with Solid Components Detected on Low-Dose CT and Confirmed as Invasive Adenocarcinoma

(Source: Cellina *et al.*, 2023)

As an illustration, patients of institutions that incorporate LDCT in routine preventive care procedures have a smooth interaction and follow-up. The barriers in institutions, though, are the resource limitation, the lack of workforce, and the inconsistency of insurance coverage that curtail the scaling of the program. It has been indicated that quality assurance structures and centralized screening registries improve efficiency and equity in the programs. Additionally, institutional leadership is significant in the process of sustaining LDCT programs so that cancer screening is a priority area in the wider context of public health (Bonney *et al*., 2022). As presented in case studies, those institutions that have implemented evidence-based guidelines in their practice, like those of the U.S. Preventive Services Task Force, record a significant decrease in the mortality rate of lung cancer. Finally, the institutional implementation is the key to whether the benefits of LDCT proved to be real (reduced mortality, early diagnosis, accurate diagnosis) can be transformed into the practical benefit of high risk patient groups.

DISCUSSION

The results are critically discussed and the advantages and disadvantages of low-dose CT in lung cancer screening in high-risk patients. The evidence actually illustrates significant death rate reduction outcomes, and indeed trials like NLST and NELSON have validated that LDCT is a significant way of reducing specific death rates of lung cancer as compared to the use of chest radiography (Rajabi *et al.*, 2024). Nonetheless, they can only be achieved when regular screening is observed, which in most institutions is dismal. This disparity casts doubts on institutional obstacles, such as patient education, socioeconomic disparities, and institutional focus on preventive care. Although the early detection rates are impressive because they usually double the rate of stage I diagnoses, the issue of false positives still exists, and additional diagnostic imaging accuracy systems such as Lung-RADS are needed. Despite these precautions, institutional differences in the expertise of radiologists and follow-up routes may jeopardize results (Mendoza *et al.*, 2022). Further, the institutional implementation effect is not even; highly integrated programs realize a quantifiable success, whereas resource constrained environments can barely support LDCT programs. Therefore, LDCT is an effective instrument of cancer screening, but its practical applicability relies on the capacity of the institutions, patient involvement, and the equitable access. A critical synthesis indicates that the potential to transform the clinical outcome of lung cancer by the LDCT can be underutilized unless we deal with these systemic obstacles, which limits the potential impact of LDCT in lowering the incidence of lung cancer death among high risk groups (Pires *et al*., 2024).

CONCLUSION

Low dose CT has emerged a revolutionary technique in lung cancer screening among high risk groups of patients by providing quantifiable improvements in mortality reduction outcomes, early detection rates, and clinical outcomes. Large-scale trials like NLST and NELSON findings indicate that LDCT is a very useful test in enhancing survival because it detects cancers at very early stages when treatment is most effective. Nevertheless, institutional case studies have shown that the entire promise of the LDCT is constrained by inadequate screening rates, access disparities, and inconsistencies in the diagnostic imaging error rate. The efforts targeted by the required implementation of the institutional level also entail the use of uniform procedures, marketing strategies with the patient, and balanced resource distribution to achieve uniform

outcomes in various healthcare environments. Finally, LDCT screening is a significant development in cancer screening, although its effectiveness relies on the capacity to overcome the system level obstacles and integrate evidence-based interventions into institutions in order to use the maximum benefits of LDCT screening among the high risk groups.

REFERENCES

[1] Behr, C. M., Oude Wolcherink, M. J., IJzerman, M. J., Vliegenthart, R., & Koffijberg, H. (2023). Population-based screening using low-dose chest computed tomography: a systematic review of health economic evaluations. Pharmacoeconomics, 41(4), 395-411. Retrieved at https://link.springer.com/article/10.1007/s40273-022-01238-3

[2] Bonney, A., Malouf, R., Marchal, C., Manners, D., Fong, K. M., Marshall, H. M., ... & Manser, R. (2022). Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database of Systematic Reviews, (8). Retrieved at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013829.pub2/abstract

[3] Cavers, D., Nelson, M., Rostron, J., Robb, K. A., Brown, L. R., Campbell, C., ... & Weller, D. (2022). Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature. Respiratory research, 23(1), 374. Retrieved at https://link.springer.com/article/10.1186/s12931-022-02255-8

[4] Cellina, M., Cacioppa, L. M., Cè, M., Chiarpenello, V., Costa, M., Vincenzo, Z., Pais, D., Bausano, M. V., Rossini, N., Bruno, A., & Floridi, C. (2023). Artificial Intelligence in Lung Cancer Screening: The Future Is Now. Cancers, 15(17), 4344. Retrieved at https://doi.org/10.3390/cancers15174344

[5] Chalian, H., McAdams, H.P., Lee, Y., Duan, F., Wu, Y., Khoshpouri, P. and Patz Jr, E.F., 2022. Mediastinal lymphadenopathy in the National Lung Screening Trial (NLST) is associated with interval lung cancer. Radiology, 302(3), pp.684-692. Retrieved at https://pubs.rsna.org/doi/abs/10.1148/radiol.210522

[6] Europe.com. (2023, July 26). AI uses low-dose CT data for mortality prediction. Healthcare-In-Europe.com. Retrieved at https://healthcare-in-europe.com/en/news/ai-low-dose-ct-data-mortality-prediction.html

[7] Fel, T., Boutin, V., Béthune, L., Cadène, R., Moayeri, M., Andéol, L., ... & Serre, T. (2023). A holistic approach to unifying automatic concept extraction and concept importance estimation. Advances in Neural Information Processing Systems, 36, 54805-54818. Retrieved at https://proceedings.neurips.cc/paper_files/paper/2023/hash/abf3682c9cf9245a0294a4bebe4544ff-Abstract-Conference.html